

1 James R. Condo (#005867)
2 Amanda C. Sheridan (#027360)
3 SNELL & WILMER L.L.P.
4 One Arizona Center
5 400 E. Van Buren, Suite 1900
Phoenix, AZ 85004-2204
Telephone: (602) 382-6000
jcondo@swlaw.com
asheridan@swlaw.com

6 Richard B. North, Jr. (admitted *pro hac vice*)
7 Georgia Bar No. 545599
Matthew B. Lerner (admitted *pro hac vice*)
8 Georgia Bar No. 446986
NELSON MULLINS RILEY & SCARBOROUGH LLP
9 Atlantic Station
201 17th Street, NW, Suite 1700
Atlanta, GA 30363
Telephone: (404) 322-6000
richard.north@nelsonmullins.com
matthew.lerner@nelsonmullins.com

10 *Attorneys for Defendants*
11 *C. R. Bard, Inc. and*
12 *Bard Peripheral Vascular, Inc.*

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF ARIZONA**

IN RE: Bard IVC Filters Products Liability Litigation

No. 2:15-MD-02641-DGC

**DEFENDANTS' RESPONSE IN
OPPOSITION TO PLAINTIFF'S
MOTION *IN LIMINE* NO. 9 TO
EXCLUDE EVIDENCE OF TRADE
ASSOCIATIONS, SOCIETIES, OR
ORGANIZATIONS**

(Assigned to the Honorable David G. Campbell)

1 Defendants C. R. Bard, Inc. and Bard Peripheral Vascular, Inc. (collectively
 2 “Bard”) submit this response in opposition to Plaintiff’s Motion *in Limine* No. 9 and
 3 respectfully show the Court as follows:

4 **ARGUMENT AND CITATION OF AUTHORITY**

5 **A. Such Material Is Admissible as Non-Hearsay, an Exception to Hearsay, and as
 6 a Basis of Opinions Offered by Bard’s Medical Experts.**

7 The Plaintiff argues that “medical societies’ statements constitute inadmissible
 8 hearsay . . . to the extent that they are offered for the truth of the matter asserted.” (Pl.’s
 9 Mot. at 2.) Bard need not be offering such statements for the truth of the matter asserted,
 10 however. Therefore, the Plaintiff’s argument fails.

11 Under Georgia’s risk-utility test for design defect, juries may consider, among
 12 other factors, the likelihood of the danger, the user’s knowledge of the product, publicity
 13 surrounding the danger, common knowledge, the state of the art at the time the product is
 14 manufactured, and proof of compliance with industry-wide practices. *See Banks v. ICI
 15 Americas, Inc.*, 450 S.E.2d 671, 675 n.6 (Ga. 1994). Statements of medical societies,
 16 about IVC filters and reported complications with IVC filters, regardless of truth of those
 17 statements, are relevant to the jury’s consideration of these risk-utility factors. For
 18 example, the *Quality Improvement Guidelines for Percutaneous Permanent Inferior Vena
 19 Cava Filter Placement for the Prevention of Pulmonary Embolism*, published periodically
 20 since 2001 by the Society of Interventional Radiology (“SIR”) addresses reported rates of
 21 IVC filter complications generally seen by physicians as reported in the medical literature.
 22 The SIR Guidelines discuss the complications of fracture, tilt, migration, and penetration
 23 of the IVC, citing to articles in the medical literature. The jury should be able to consider
 24 this evidence when weighing whether these complications amounted to “common
 25 knowledge,” and when assessing “publicity surrounding the danger” of these
 26 complications, for instance.

27 Likewise, such statements that were provided to the medical community (whether
 28 true or not), are relevant to the jury’s consideration of whether Bard’s warnings were

1 adequate and whether any such failure caused her physician to use the G2® Filter instead
 2 of a different filter. *See, e.g., Thornton v. E.I. Du Pont de Nemours & Co.*, 22 F.3d 284,
 3 289 (11th Cir. 1994) (discussing duty to warn under Georgia law of “nonobvious”
 4 foreseeable dangers and the need to provide “an adequate warning”).

5 Even if statements by medical societies are offered for the truth of the matter
 6 asserted, they reflect statements in learned treatises, periodicals, or pamphlets under
 7 Federal Rule of Evidence 803(18), and therefore are admissible as an exception to the
 8 hearsay rule. And regardless of hearsay, Bard’s medical experts have relied on, and
 9 properly disclosed their reliance on, the SIR Guidelines in forming their opinions, and
 10 therefore Bard’s experts’ opinions based on the SIR Guidelines are admissible under Rule
 11 703, and were unchallenged by the Plaintiff in any *Daubert* motions.

12 Finally, counsel for the Plaintiff may cross examine witnesses who address the SIR
 13 Guidelines and any other associations, trade groups, organizations, or societies of
 14 physicians; Plaintiff may also call her own witnesses, and argue to the jury about the
 15 relative significance of such statements and non-statements.¹

16 Accordingly, what medical societies, like the SIR, say or do not say about risks of
 17 IVC filters generally and/or of Bard’s G2® Filter specifically are relevant to the jury’s
 18 consideration of the Plaintiff’s design and warning claims and should be admissible on
 19 numerous grounds.

20 **B. *Daubert* and Rule 703 Are Inapplicable.**

21 The Plaintiff’s argument that Bard will attempt to offer expert opinions through
 22 fact witnesses is inaccurate. The SIR Guidelines, however, were discussed routinely
 23 among Bard employees and with the FDA. These fact witnesses should be permitted to
 24 testify and be cross examined about things they said and actions they took during the

25
 26 ¹ Plaintiff incorrectly argues that absence of a statement from medical societies constitutes
 27 hearsay. *See e.g., Llamas v. Seibel*, No. 16-CV-05812-WHO, 2017 WL 3782175, at *8
 28 (N.D. Cal. Aug. 31, 2017) (“Testimony regarding the *absence* of a statement is not
 hearsay.”) (emphasis original); *see also, e.g.*, Fed. R. Evid. 801 (“‘Statement’ means a
 person’s oral assertion, written assertion, or nonverbal conduct, if the person intended it as
 an assertion.”).

1 course of their employment concerning the SIR Guidelines. Moreover, the Plaintiff has
 2 developed extensive expert opinion to rebut any testimony that counsel purports to be
 3 concerned about. (*See e.g.*, Expert Report of Drs. Kinney, Roberts, and Kalva, Doc. 7300
 4 Exhibit G, at pp. 86-104.) As such, *Daubert* and Rule 703 are inapplicable.

5 **C. Any Danger of Prejudice or Waste of Time Is Not Substantially Outweighed
 6 by the Probative Value.**

7 The foundation for the Plaintiff's argument is that, in other cases, Bard used the
 8 SIR Guidelines to establish acceptable safety thresholds and complication rates. But the
 9 Plaintiff's claim is inaccurate, and the Plaintiff has cited nothing to the contrary. The
 10 Plaintiff also claims that the SIR Guidelines are irrelevant because they concern only
 11 permanent filters. But the G2® Filter at issue in Ms. Booker's case was first cleared as a
 12 permanent filter before receiving clearance as a retrievable filter. And although the 2001
 13 and 2003 SIR Guidelines concern permanent filters, the 2011, 2016, and 2017 SIR
 14 Guidelines concern both permanent and retrievable filters. Finally, the Plaintiff argues
 15 that the SIR Guidelines will result in "mini-trials," but efficient management of the
 16 evidence and adherence to the Court's time limits will avoid this issue. As discussed
 17 above, the SIR Guidelines are relevant to the jury's consideration of Georgia's risk-utility
 18 test and the Plaintiff's failure-to-warn claim, and they are factually relevant to what Bard
 19 did and said regarding its G2® Filter. Indeed, excluding the SIR Guidelines would risk
 20 confusing the jury because many relevant events in this case refer to or relate to the SIR
 21 Guidelines, and discussion of the SIR Guidelines therefore will provide the jury with
 22 necessary context. In short, the Plaintiffs have not demonstrated at this *in limine* stage
 23 that the probative value of the SIR Guidelines, and any other evidence of trade
 24 associations, societies, or organizations, is "substantially outweighed" by the danger of
 25 unfair prejudice and "unnecessary mini trials."

26 **CONCLUSION**

27 For these reasons, Bard respectfully requests that this Court deny the Plaintiff's
 28 Motion *in Limine* No. 9.

RESPECTFULLY SUBMITTED this 9th day of February, 2018.

s/ Richard B. North, Jr.
Richard B. North, Jr.
Georgia Bar No. 545599
Matthew B. Lerner
Georgia Bar No. 446986
NELSON MULLINS RILEY & SCARBOROUGH, LLP
Atlantic Station
201 17th Street, NW / Suite 1700
Atlanta, GA 30363
PH: (404) 322-6000
FX: (404) 322-6050
richard.north@nelsonmullins.com
matthew.lerner@nelsonmullins.com

James R. Condo (#005867)
Amanda Sheridan (#027360)
SNELL & WILMER L.L.P.
One Arizona Center
400 E. Van Buren
Phoenix, AZ 85004-2204
PH: (602) 382-6000
jcondo@swlaw.com
asheridan@swlaw.com

**Attorneys for Defendants C. R. Bard, Inc. and
Bard Peripheral Vascular, Inc.**

CERTIFICATE OF SERVICE

I hereby certify that on this 9th day of February, 2018, the foregoing was electronically filed with the Clerk of Court using the CM/ECF system which will automatically send email notification of such filing to all attorneys of record.

s/Richard B. North, Jr.
Richard B. North, Jr.

Nelson Mullins Riley & Scarborough

LLP
201 17th Street NW Suite 1700
Atlanta, GA 30363
(404) 322-6000

2001 17th Street NW, Suite 1700
Atlanta, GA 30363
(404) 322-6000